Background: Allergic rhinitis is a common disease affects about 5 to 22% from general population. Botulinum toxin is a neurotoxic protein assumed to lead to symptomatic control of intermittent allergic rhinitis. Objectives: To compare between utilization of botulinum toxin type A versus fluticasone furoate in treatment of intermittent allergic rhinitis. Patients and Methods: A randomized clinical controlled trial study created on seventy two adult patients with intermittent allergic rhinitis divided into two groups; Group B (BTX-A) and Group F (fluticasone furoate). Results: After one month the mean intensity of nasal symptoms according to VAS among the Group B (BTX-A) sneezing was 2.41 while 2.16 in Group F (fluticasone furoate). The difference is not statistically significant. Conclusions: Intranasal injection of Botulinum A(BTX-A) is a highly effective, safe, and simple procedure, with lasting effect for one month in intermittent allergic rhinitis. It might be used in some patients with intermittent allergic rhinitis.
